Attention Deficit Hyperactivity Disorder (ADHD) (Central Nervous System) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Attention Deficit Hyperactivity Disorder – Drugs In Development, 2021, provides an overview of the Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline landscape.

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination and inability to sustain attention on tasks or activities. Treatment includes analeptics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Attention Deficit Hyperactivity Disorder – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 5, 9, 11, 23, 9 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (Central Nervous System).

– The pipeline guide reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Attention Deficit Hyperactivity Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Attention Deficit Hyperactivity Disorder (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

3Z ehf

4P-Pharma SAS

ABVC BioPharma Inc

AgoneX Biopharmaceuticals Inc

Altus Formulation Inc

Amarantus Bioscience Holdings Inc

Arbor Pharmaceuticals LLC

Attentive Therapeutics Inc

Avekshan LLC

BCWorld Pharm Co Ltd

Cennerv Pharma (S) Pte Ltd

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Commave Therapeutics SA

Curemark LLC

DD Therapeutics LLC

DURECT Corp

EncepHeal Therapeutics Inc

Ensysce Biosciences Inc

Highland Therapeutics Inc

Hyloris Pharmaceuticals SA

INVENT Pharmaceuticals Inc

Kashiv BioSciences LLC

KemPharm Inc

Table of Contents

Table of Contents

Introduction

Attention Deficit Hyperactivity Disorder (ADHD) - Overview

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Development

Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics Assessment

Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development

Attention Deficit Hyperactivity Disorder (ADHD) - Drug Profiles

Attention Deficit Hyperactivity Disorder (ADHD) - Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) - Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 3Z ehf, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 4P-Pharma SAS, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by ABVC BioPharma Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by AgoneX Biopharmaceuticals Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Altus Formulation Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arbor Pharmaceuticals LLC, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Attentive Therapeutics Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Avekshan LLC, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cennerv Pharma (S) Pte Ltd, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Commave Therapeutics SA, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, 2021

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports